Design Therapeutics, Inc. Common Stock
Veridion Score
Composite trend over time
Why is DSGN moving today?
Design Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the research and development of GeneTAC molecules, which are a novel class of small-molecule gene targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. Its pipeline includes Friedreich Ataxia, FECD, DM1, and Huntington's Disease. The company operates in one operating and reportable segment focused on utilizing the company's proprietary GeneTAC platform to design and develop therapeutic candidates for inherited diseases driven by nucleotide repeat expansion.
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
Warehouse intelligence for DSGN.
DSGN insider activity
Design Therapeutics, Inc. Common Stock
No multi-insider buying cluster in the last 90 days
Net selling: -$3.0M across loaded Form 4 rows.
Loaded official disclosures do not show all three sources aligned on this ticker.
| Filing date | Trade date | Insider | Title | Type | Price | Qty | Owned | Value | Receipt |
|---|---|---|---|---|---|---|---|---|---|
| 2025-08-14 | 2025-08-13 | William Arsani | Insider | sell | $5.25 | 217,627 | 1,000,000 | $1.1M | SEC Form 4 |
| 2025-08-14 | 2025-08-13 | William Arsani | Insider | sell | $5.25 | 345,000 | 2,655,000 | $1.8M | SEC Form 4 |
DSGN contract awards, year to date.
Public federal awards linked to this ticker.
DSGN lobbying filings, year to date.
Registered lobbying filings matched to Design Therapeutics, Inc. Common Stock.